-
![Substituted imidazo[1,2-a]pyrazines as TNF activity modulators](/abs-image/US/2016/10/25/US09475820B2/abs.jpg.150x150.jpg)
11.发明授权公开(公告)号：US09475820B2
公开(公告)日：2016-10-25
申请号：US14414299
申请日：2013-07-05
Applicant: UCB Biopharma SPRL
Inventor： Jonathan Mark Bentley , Daniel Christopher Brookings , Julien Alistair Brown , Thomas Paul Cain , Laura Jane Gleave , Alexander Heifetz , Victoria Elizabeth Jackson , Craig Johnstone , Deborah Leigh , James Madden , John Robert Porter , Matthew Duncan Selby , Zhaoning Zhu
IPC: A61K31/4985 , C07D241/36 , C07D491/107 , C07D487/04 , A61K31/506 , A61K31/5377 , A61K31/5513 , C07D451/02 , C07D471/08
CPC classification number: C07D491/107 , A61K31/4985 , A61K31/506 , A61K31/5377 , A61K31/5513 , C07D451/02 , C07D471/08 , C07D487/04
Abstract: A series of imidazo[1,2-a]pyrazine derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. The imidazo[1,2-a]pyrazine derivatives of the disclosure are of general formula
-
12.发明申请公开(公告)号：US20160304514A1
公开(公告)日：2016-10-20
申请号：US15101203
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
IPC: C07D471/04 , A61K31/437
CPC classification number: C07D471/04 , A61K31/437
Abstract: A series of substituted 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Abstract translation: 因此，式（I）的一系列取代的4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶衍生物是人TNFα活性的有效调节剂，因此在治疗和/或 预防各种人类疾病，包括自身免疫性和炎症性疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱 眼部疾病; 和肿瘤疾病。
-
公开(公告)号：US10093652B2
公开(公告)日：2018-10-09
申请号：US15038287
申请日：2014-12-08
Applicant: UCB Biopharma SPRL
Inventor： Jag Paul Heer , Victoria Elizabeth Jackson , Boris Kroeplien , Fabien Claude Lecomte , John Robert Porter
IPC: A61K35/28 , A01N1/02 , G01N33/569 , C12N5/0789 , C07D401/10 , C07D235/12 , A61K31/4439
Abstract: A series of substituted 4,5,6,7-tetrahydrobenzimidazole derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US09988383B2
公开(公告)日：2018-06-05
申请号：US15100697
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
IPC: C07D473/00 , C07D473/32 , A61K31/5377
CPC classification number: C07D473/00 , A61K31/5377 , C07D473/32
Abstract: A series of substituted purine derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US09932342B2
公开(公告)日：2018-04-03
申请号：US15100690
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
Inventor： Mezher Hussein Ali , Daniel Christopher Brookings , Julien Alistair Brown , Victoria Elizabeth Jackson , Boris Kroeplien , John Robert Porter
IPC: C07D487/04 , A61K31/519 , A61K31/5377
CPC classification number: C07D487/04 , A61K31/519 , A61K31/5377
Abstract: A series of substituted imidazo[1,2-a]pyrimidine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
Patent Agency Ranking
16.发明申请公开(公告)号：US20160297837A1
公开(公告)日：2016-10-13
申请号：US15100825
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
Inventor： Rikki Peter Alexander , Jonathan Mark Bentley , Gareth Neil Brace , Daniel Christopher Brookings , Praful Tulshi Chovatia , Hervé Jean Claude Deboves , Craig Johnstone , Elizabeth Pearl Jones , Boris Kroeplien , Fabien Claude Lecomte , James Madden , Craig Miller , John Robert Porter , Matthew Duncan Selby , Michael Alan Shaw , Darshan Gunvant Vaidya , Ian Andrew Yule
IPC: C07D519/00 , A61K31/4709 , A61K31/4355 , A61K31/538 , A61K31/5383 , C07D471/04
CPC classification number: C07D519/00 , A61K31/4355 , A61K31/4709 , A61K31/538 , A61K31/5383 , C07D471/04
Abstract: A series of substituted benzimidazole, imidazo[1,2-a]pyridine and pyrazolo[1,5-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Abstract translation: 一系列取代的苯并咪唑，咪唑并[1,2-a]吡啶和吡唑并[1,5-a]吡啶衍生物及其类似物是人类TNFα活性的有效调节剂，因此在治疗和/或预防中有益 各种人类疾病，包括自身免疫性和炎症性疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱 眼部疾病; 和肿瘤疾病。
-
公开(公告)号：US20150152065A1
公开(公告)日：2015-06-04
申请号：US14406848
申请日：2013-06-11
Applicant: UCB Biopharma SPRL
Inventor： Daniel Christopher Brookings , Mark Daniel Calmiano , Ellen Olivia Gallimore , Helen Tracey Horsley , Martin Clive Hutchings , James Andrew Johnson , Boris Kroeplien , Fabien Claude Lecomte , Martin Alexander Lowe , Timothy John Norman , John Robert Porter , Joanna Rachel Quincey , James Thomas Reuberson , Matthew Duncan Selby , Michael Alan Shaw , Zhaoning Zhu , Anne Marie Foley
IPC: C07D235/12 , C07D401/04 , A61K31/4439 , A61K31/454 , C07D405/06 , A61K31/4192 , C07D403/04 , A61K31/4709 , A61K31/4725 , A61K31/444 , C07D401/14 , A61K31/5377 , A61K31/541 , A61K31/551 , C07D491/107 , A61K31/506 , A61K31/4184
CPC classification number: C07D235/12 , A61K31/4184 , A61K31/4192 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4709 , A61K31/4725 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/551 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/06 , C07D491/107
Abstract: A series of benzimidazole derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Abstract translation: 因此，作为人TNFα活性的有效调节剂的一系列苯并咪唑衍生物有益于治疗和/或预防各种人类疾病，包括自身免疫和炎性疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱 眼部疾病; 和肿瘤疾病。
-
公开(公告)号：US20180134728A1
公开(公告)日：2018-05-17
申请号：US15580059
申请日：2016-06-07
Applicant: UCB Biopharma SPRL
Inventor： Gareth Neil Brace , Prafulkumar Tulshibhai Chovatia , Gregory Foulkes , James Andrew Johnson , Severine Danielle Jones , Boris Kroeplien , Fabien Claude Lecomte , Pui Leng Loke , Martin Alexander Lowe , Ajay Mandal , Timothy John Norman , Christopher Francis Palmer , Yolanda Pérez-Fuertes , John Robert Porter , Donald Smyth , Giancarlo Trani , Muhammed Uddin , Zhaoning Zhu
IPC: C07D498/04 , A61P29/00 , A61P25/00 , A61P3/00 , A61P27/02 , A61P23/00 , A61P9/00 , A61P35/00 , A61K31/5383 , C07D413/14 , A61K31/538 , C07D413/06 , C07D471/04 , C07D413/12 , A61K31/473 , A61K31/4375 , A61K31/4725 , A61K31/444 , A61K31/423 , A61K31/4545 , A61K31/55 , C07D519/00
CPC classification number: C07D498/04 , A61K31/423 , A61K31/4375 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/473 , A61K31/538 , A61K31/5383 , A61K31/55 , A61P3/00 , A61P9/00 , A61P23/00 , A61P25/00 , A61P27/02 , A61P29/00 , A61P35/00 , C07D401/06 , C07D413/06 , C07D413/12 , C07D413/14 , C07D471/04 , C07D519/00
Abstract: A series of substituted 3,4-di-hydro-2H-.1,4-benzoxazin-3-one derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US09920052B2
公开(公告)日：2018-03-20
申请号：US15039199
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
Inventor： Victoria Elizabeth Jackson , John Robert Porter
IPC: C07D471/04 , A61K31/437 , A61K31/496 , A61K31/5377
CPC classification number: C07D471/04 , A61K31/437 , A61K31/496 , A61K31/5377
Abstract: A series of substituted 1H imidazo[4,5-c]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US09873703B2
公开(公告)日：2018-01-23
申请号：US15038733
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
Inventor： Mezher Hussein Ali , Daniel Christopher Brookings , Julien Alistair Brown , Martin Clive Hutchings , Victoria Elizabeth Jackson , Boris Kroeplien , John Robert Porter , Joanna Rachel Quincey
IPC: C07D487/04 , A61K31/5025 , A61K31/506 , A61K31/5377
CPC classification number: C07D487/04 , A61K31/5025 , A61K31/506 , A61K31/5377
Abstract: A series of substituted imidazo[1,2-b]pyridazine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
-
-
-
-
-
-
-
-
Search Results
34
records
(took 0.033 seconds)
